HIF2 and endocrine neoplasia: an evolving story

    1. Eamonn R Maher1,2
    1. 1Department of Medical Genetics, University of Cambridge, Cambridge, UK and
      2Department of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Research Campus, Cambridge CB2 0QQ, UK
    1. (Correspondence should be addressed to E R Maher; Email: erm1000{at}medschl.cam.ac.uk)

    Abstract

    In this issue of Endocrine-Related Cancer, Toledo et al. report the identification of activating mutations in the HIF2 (EPAS1) transcription factor in a subset of sporadic pheochromocytomas and paragangliomas. These findings add significantly to an evolving and complex story of the role of hypoxic gene response pathways in human endocrine neoplasia.

    • Revision received 23 April 2013
    • Accepted 25 April 2013
    • Made available online as an Accepted Preprint 7 May 2013
    | Table of Contents

    This Article

    1. doi: 10.1530/ERC-13-0146 Endocr Relat Cancer 20 C5-C7
    1. Abstract
    2. Full Text
    3. Full Text (PDF)
    4. All Versions of this Article:
      1. ERC-13-0146v1
      2. 20/3/C5 most recent

    Article Metrics

    1. Article Usage Statistics

    New Articles: issue in progress

    1. November 2017, 24 (11)
    1. Current Issue
    1. Alert me to new issues of Endocrine-Related Cancer

    Most